AnorMED Inc.

AnorMEDInc.

AnorMED's core strength involves the application of chemistry, biochemistry and biology to the discovery and development of small molecule therapeutics for the treatment of diseases including inflammation, cancer and HIV. AnorMED's late stage clinical products include: Foznol, exclusively licensed to Shire Pharmaceuticals Group plc, which is on track for a US filing and European market approval by mid-year 2002; AMD-473, a new platinum based anti-cancer agent, in ongoing Phase II trials; AMD-3100, a potential new agent for stem cell transplant in cancer patients currently in a Phase I trial; and Apomate, a prognostic imaging agent for cancer and other diseases, which employs a technology licensed to North American Scientific Inc. by AnorMED. The Company is also focused on a novel class of compounds that target specific receptors known to be involved in HIV, rheumatoid arthritis, asthma and cancer. AnorMED continues to build upon its drug discovery and clinical development capabilities to support the rapid advancement of its most promising therapeutic candidates into clinical trials and to attract corporate partners.

Company Details

Year Established: 1996

Number of Employees: 103

Company Information

Michael Abrams
Title: President

Bill Adams
Title: Chief Financial Officer
Telephone: (604) 530-1057
Fax: (604) 530-0976
Email: Click Here

Geoff Henson
Title: Chief Operating Officer
Email: Click Here

Carla Sondrick
Title: Corp. Communications Co-ordinator
Telephone: (604) 530-1057
Fax: (604) 530-0976
Email: Click Here

Carla Fondrick
Title: Corp. Communications Co-ordinator
Telephone: (604) 530-1057
Fax: (604) 530-0976
Email: Click Here

Products

Pharmaceuticals

Services